Related Experiment Video
Updated: Jul 19, 2026
Fertility Preservation in Patients with Severe Ovarian Dysfunction
Published on: March 25, 2021
Fertility sparing therapy in a patient with placental site trophoblastic tumor: a case report
T Michael Numnum1, Larry C Kilgore, Michael G Conner
1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Alabama at Birmingham,618 19th Street South, OHB 538, Birmingham, AL 35249, USA. tmnumnum@yahoo.com
Background:
Placental site trophoblastic tumor (PSTT) is a rare form of gestational trophoblastic disease (GTD) that is generally resistant to conventional chemotherapeutic treatment. Patients with localized disease are usually managed with hysterectomy.
Case:
A 29-year-old female presented with vaginal bleeding and an elevated serum human chorionic gonadotropin (HCG). After initial observation, the patient experienced continued vaginal bleeding and a persistently elevated HCG. Therefore, she underwent a dilation and curettage and final pathology revealed PSTT. Since the patient desired future fertility, the patient received combination chemotherapy with etoposide, methotrexate, actinomycin-D followed by etoposide and cisplatin (EMA-EP). The patient had a complete response to chemotherapy and subsequently delivered a term infant 2 years after completion of therapy.
Conclusion:
PSTT is thought to be a chemoresistant disease and the preferred method of treatment is hysterectomy or local uterine resection. However, combination chemotherapy is a reasonable option in a properly counseled patient who strongly desires future fertility.
